SPECTRUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.sppirx.com
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 648
- Registration Number
- NCT03318939
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Santa Monica, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
- Conditions
- Bladder Cancer
- Interventions
- Drug: PlaceboDrug: Qapzola
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT03224182
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT03135951
- Locations
- 🇺🇸
Research Center, Anaheim, California, United States
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
- Conditions
- NeutropeniaBreast Cancer
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 237
- Registration Number
- NCT02953340
- Locations
- 🇺🇸
Millennium Oncology, Pembroke Pines, Florida, United States
🇺🇸Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Lakes Research, LLC, Miami Lakes, Florida, United States
A Study of IGN002 for Refractory NHL
- Conditions
- NHL
- Interventions
- Biological: IGN002
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Registration Number
- NCT02847949
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT02659514
- Locations
- 🇺🇸
Clearview Cancer Center, Huntsville, Alabama, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Marin Cancer Care, Inc, Greenbrae, California, United States
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
- Conditions
- NeutropeniaBreast Cancer
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 406
- Registration Number
- NCT02643420
- Locations
- 🇺🇸
NEA Baptist Clinic | Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States
🇺🇸CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02563561
- Locations
- 🇺🇸
The Urology Center of Colorado, Denver, Colorado, United States
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Biological: IGN002
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02519270
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸UPMC, Pittsburgh, Pennsylvania, United States
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01773785
- Locations
- 🇺🇸
University of Miami Hospitals & Clinics/ Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Associates in Oncology and Hematology, Chattanooga, Tennessee, United States